- Home
- DTIL vs IKNA Comparison
DTIL vs IKNA Comparison
Compare DTIL & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- IKNA
- Stock Information
- Founded
- DTIL 2006
- IKNA 2016
- Country
- DTIL United States
- IKNA United States
- Employees
- DTIL N/A
- IKNA N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- IKNA Health Care
- Exchange
- DTIL Nasdaq
- IKNA Nasdaq
- Market Cap
- DTIL 51.6M
- IKNA 52.1M
- IPO Year
- DTIL 2019
- IKNA 2021
- Fundamental
- Price
- DTIL $5.01
- IKNA $1.27
- Analyst Decision
- DTIL Strong Buy
- IKNA Buy
- Analyst Count
- DTIL 2
- IKNA 2
- Target Price
- DTIL $47.00
- IKNA $3.00
- AVG Volume (30 Days)
- DTIL 74.8K
- IKNA 109.0K
- Earning Date
- DTIL 05-15-2025
- IKNA 05-08-2025
- Dividend Yield
- DTIL N/A
- IKNA N/A
- EPS Growth
- DTIL N/A
- IKNA N/A
- EPS
- DTIL N/A
- IKNA N/A
- Revenue
- DTIL $51,141,000.00
- IKNA N/A
- Revenue This Year
- DTIL N/A
- IKNA N/A
- Revenue Next Year
- DTIL $30.20
- IKNA N/A
- P/E Ratio
- DTIL N/A
- IKNA N/A
- Revenue Growth
- DTIL N/A
- IKNA N/A
- 52 Week Low
- DTIL $3.61
- IKNA $0.97
- 52 Week High
- DTIL $13.32
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- DTIL 49.26
- IKNA 53.94
- Support Level
- DTIL $4.72
- IKNA $1.10
- Resistance Level
- DTIL $5.10
- IKNA $1.20
- Average True Range (ATR)
- DTIL 0.26
- IKNA 0.08
- MACD
- DTIL 0.01
- IKNA 0.01
- Stochastic Oscillator
- DTIL 50.16
- IKNA 74.70
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.